ClinicalTrials.gg
RecruitingNCT07302659PROTECT-CABGUpdated Nov 17, 2026

Aortic No-Touch vs Partial Aortic Clamping in Off-Pump CABG

An interventional study of Aortic no-touch coronary artery bypass grafting (RIMA-SVG) and Conventional off-pump CABG with partial clamping of the ascending aorta (Ao-SVG) in Coronary Artery Bypass Graft (CABG), sponsored by China National Center for Cardiovascular Diseases. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 17, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To explore surgical strategies that reduce perioperative neurologic complications in cardiovascular surgery, with the aim of improving perioperative outcomes and quality of life while reducing the socioeconomic burden. Specifically:

This multicenter, randomized controlled clinical trial will evaluate the benefits of a novel aortic no-touch technique in reducing perioperative silent brain infarction(SBI) among patients undergoing surgical treatment for coronary artery disease. The findings are expected to provide a safe and effective myocardial revascularization strategy for individuals at high risk of cerebral ischemia.

02

Conditions studied

  • Coronary Artery Bypass Graft (CABG)

Keywords

  • coronary artery bypass graft
  • Silent Brain Infarction
03

In context

Lead sponsor

China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (>18 years old) with multivessel coronary artery disease who are scheduled to undergo isolated off-pump coronary artery bypass grafting and who provide to participate in this study.

Exclusion criteria

Exclusion Criteria:

  • Indications for cardiopulmonary bypass surgery (or no to on-pump surgery);
  • Great saphenous vein is unsuitable for use as a graft conduit;
  • Subclavian artery stenosis or occlusion, or any contraindication to the use of the internal mammary artery as a graft conduit;
  • History of previous cardiac surgery;
  • Emergency surgery;
  • Inability to apply an aortic clamp due to severe ascending aortic calcification;
  • Expected inability to tolerate MRI or contraindications to MRI (e.g., known intolerance to MRI, an implanted permanent pacemaker, or an anticipated need for permanent pacemaker implantation);
  • Inability to complete neurocognitive assessment due to language barriers or visual/hearing impairment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
380 participants (estimated)

Study arms

  • Active comparator
    Traditional off-pump coronary artery bypass grafting (Ao-SVG)

    Off-pump CABG with proximal saphenous vein graft (SVG) anastomoses constructed on the ascending aorta using a partial-occlusion (side-biting) clamp.

    Procedure: Conventional off-pump CABG with partial clamping of the ascending aorta (Ao-SVG)

  • Experimental
    Aortic no-touch coronary artery bypass grafting (RIMA-SVG)

    Aortic no-touch off-pump CABG in which the saphenous vein graft (SVG) is anastomosed to the right internal mammary artery (RIMA) as a composite graft, avoiding any clamping or manipulation of the ascending aorta.

    Procedure: Aortic no-touch coronary artery bypass grafting (RIMA-SVG)

Interventions

  • ProcedureAortic no-touch coronary artery bypass grafting (RIMA-SVG)

    Ascending aortic no-touch CABG with saphenous vein graft (SVG) anastomosed to the right internal mammary artery (RIMA)

  • ProcedureConventional off-pump CABG with partial clamping of the ascending aorta (Ao-SVG)

    Off-pump CABG with proximal saphenous vein graft (SVG) anastomoses constructed on the ascending aorta using a partial-occlusion (side-biting) clamp.

06

What researchers measure

Primary outcomes

  1. Saphenous vein graft (SVG) occlusion rate

    Assessed by coronary computed tomography angiography (CCTA)

    Time frame: 1 year after surgery

  2. New-onset clinical stroke and silent brain infarction (SBI)

    Clinical stroke and SBI assessed at 7 ± 3 days postoperatively; SBI assessed by brain magnetic resonance imaging (MRI).

    Time frame: 7 ± 3 days after surgery

Secondary outcomes

  1. Incidence of postoperative delirium

    The incidence of delirium evaluated by CAM/CAM-ICU

    Time frame: within 5 postoperative days

  2. Incidence of perioperative neurocognitive disorder (PND)

    Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). Montreal Cognitive Assessment (MoCA; range 0-30 points, higher scores indicate better cognitive function).

    Time frame: within 7 days after surgery

  3. Perioperative major adverse cardiovascular and cerebrovascular events (MACCE)

    Major adverse cardiovascular and cerebrovascular events are defined as the composite of all-cause death, myocardial infarction, stroke and repeat revascularization.

    Time frame: within 30 postoperative days

  4. MACCE within 3 months after surgery

    Major adverse cardiovascular and cerebrovascular events are defined as the composite of all-cause death, myocardial infarction, stroke and repeat revascularization.

    Time frame: Up to 3 months after surgery (3-month follow-up)

  5. Clinical stroke within 3 months after surgery

    Time frame: Up to 3 months after surgery (3-month follow-up)

  6. Sternal complications within 3 months after surgery

    Time frame: Up to 3 months after surgery (3-month follow-up)

  7. Cognitive dysfunction at 3 months after surgery

    Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). Montreal Cognitive Assessment (MoCA; range 0-30 points, higher scores indicate better cognitive function).

    Time frame: 3 months after surgery

  8. Angina within 12 months after surgery

    Patients will complete the Seattle Angina Questionnaire (SAQ) at baseline pre-procedure and again at 12 months post CABG

    Time frame: 12 months after surgery

  9. Cognitive dysfunction at 12 months after surgery

    Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). Montreal Cognitive Assessment (MoCA; range 0-30 points, higher scores indicate better cognitive function).

    Time frame: 12 months after surgery

  10. Sternal complications within 12 months after surgery

    Time frame: Up to 12 months after surgery (12-month follow-up)

  11. Clinical stroke within 12 months after surgery

    Time frame: Up to 12 months after surgery (12-month follow-up)

  12. MACCE within 12 months after surgery

    Major adverse cardiovascular and cerebrovascular events are defined as the composite of all-cause death, myocardial infarction, stroke and repeat revascularization.

    Time frame: Up to 12 months after surgery (12-month follow-up)

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Zhao DF, Edelman JJ, Seco M, Bannon PG, Wilson MK, Byrom MJ, Thourani V, Lamy A, Taggart DP, Puskas JD, Vallely MP. Coronary Artery Bypass Grafting With and Without Manipulation of the Ascending Aorta: A Network Meta-Analysis. J Am Coll Cardiol. 2017 Feb 28;69(8):924-936. doi: 10.1016/j.jacc.2016.11.071. PubMed 28231944 ↗
  • Tachibana H, Hiraoka A, Saito K, Naito Y, Chikazawa G, Tamura K, Totsugawa T, Yoshitaka H, Sakaguchi T. Incidence and impact of silent brain lesions after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2021 Feb;161(2):636-644. doi: 10.1016/j.jtcvs.2019.09.162. Epub 2019 Oct 16. PubMed 31735394 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 24, 2025
StartActual
Mar 10, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Peking University First Hospita · Beijing, ChinaNot yet recruiting→Recruiting
  • Qingdao Cardiovascular Hospital · Qingdao, ChinaNot yet recruiting→Recruiting
  • Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen · Shenzhen, ChinaNot yet recruiting→Recruiting
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Peking University First Hospita · Beijing, ChinaNot yet recruiting→Recruiting
    • Qingdao Cardiovascular Hospital · Qingdao, ChinaNot yet recruiting→Recruiting
    • Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen · Shenzhen, ChinaNot yet recruiting→Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07302659
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Mar 10, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Lianxin Chen
Contact
chenlianx1@163.com
01088322265

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion